The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index.
Attention‐Deficit‐Hyperactivity Disorder: An Update
Abstract
Attention‐deficit‐hyperactivity disorder (ADHD) is a common neuropsychiatric disorder that impairs social, academic, and occupational functioning in children, adolescents, and adults. In patients with ADHD, neurobiologic research has shown a lack of connectivity in key brain regions, inhibitory control deficits, delayed brain maturation, and noradrenergic and dopaminergic dysfunction in multiple brain regions. The prevalence of this disorder in the United States is 6–9% in youth (i.e., children and adolescents) and 3–5% in adults. Prevalence rates for youth are similar worldwide. Children with ADHD are at greater risk than children without ADHD for substance abuse and delinquency whether or not they receive drug therapy; however, early treatment with psychoeducation as well as drug therapy and/or behavioral intervention may decrease negative outcomes of ADHD, including the rate of conduct disorder and adult antisocial personality disorder. Drug therapy is effective for all age groups, even preschoolers, and for late‐onset ADHD in adults. Stimulants, such as methylphenidate and amphetamine, are the most effective therapy and have a good safety profile; although recent concerns of sudden unexplained death, psychiatric adverse effects, and growth effects have prompted the introduction of other therapies. Atomoxetine, a nonstimulant, has no abuse potential, causes less insomnia than stimulants, and poses minimal risk of growth effects. Other drug options include clonidine and guanfacine, but both can cause bradycardia and sedation. Polyunsaturated fatty acids (fish oil), acetyl‐l‐carnitine, and iron supplements (for youth with low ferritin levels) show promise in improving ADHD symptoms. As long‐term studies show that at least 50% of youth are nonadherent with their drug therapy as prescribed over a 1‐year period, longacting formulations (administered once/day) may improve adherence. Comorbid conditions are common in patients with ADHD, but this patient population can be treated effectively with individualized treatment regimens of stimulants, atomoxetine, or bupropion, along with close monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)
American Psychiatric Association (2000) · doi:10.1176/appi.books.9780890423349 · Cited by 11,069
The worldwide prevalence of ADHD: a systematic review and metaregression analysis
Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.942 · Cited by 5,346
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886
Willcutt, E. G., Doyle, A. E., Nigg, J. T., Faraone, S. V., & Pennington, B. F. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.02.006 · Cited by 3,568
Molecular genetics of attention-deficit/hyperactivity disorder
Faraone, S. V., Perlis, R. H., Doyle, A. E., Smoller, J. W., Goralnick, J. J., Holmgren, M. A., & Sklar, P. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.024 · Cited by 2,357
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
Self-citationThe neural bases of momentary lapses in attention
Weissman, D. H., Roberts, K. C., Visscher, K. M., & Woldorff, M. G. (2006) · Nature Neuroscience · doi:10.1038/nn1727 · Cited by 1,566
ADHD and the Nature of Self-Control
Hinshaw, S. P. (1998) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-199806000-00010 · Cited by 1,194
Characterizing cognition in ADHD: beyond executive dysfunction
Castellanos, F. X., Sonuga-Barke, E. J. S., Milham, M. P., & Tannock, R. (2006) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2006.01.011 · Cited by 1,170
Bridge, J. A., Iyengar, S., Salary, C. B., Barbe, R. P., Birmaher, B., Pincus, H. A., Ren, L., & Brent, D. A. (2007) · JAMA · doi:10.1001/jama.297.15.1683 · Cited by 1,086
Research works printed but not linked: 2
- Jensen P.S., 2004, NIMH multimodal treatment study of ADHD follow‐up: 24‐month outcomes of treatment strategies for ADHD, Pediatrics, 114, 754
- 10.1161/CIRCULATIONAHA.107.189473 · DOI · Paper page
Cited by
Card, N. A., Stucky, B. D., Sawalani, G. M., & Little, T. D. (2008) · Child Development · doi:10.1111/j.1467-8624.2008.01184.x · Cited by 1,917
Hypersexual disorder: A proposed diagnosis for DSM-V
Kafka, M. P. (2010) · Archives of Sexual Behavior · doi:10.1007/s10508-009-9574-7 · Cited by 1,095
Understanding heterogeneity in clinical cohorts using normative models: Beyond case-control studies
Marquand, A. F., Rezek, I., Buitelaar, J., & Beckmann, C. F. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.12.023 · Cited by 683
Gillberg, C. (2010) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2010.06.002 · Cited by 742
Evaluating Dopamine Reward Pathway in ADHD: Clinical Implications
Volkow, N. D., Wang, G.-J., Kollins, S. H., Wigal, T. L., Newcorn, J. H., Telang, F., Fowler, J. S., Zhu, W., Logan, J., Ma, Y., et al. (2009) · JAMA · doi:10.1001/jama.2009.1308 · Cited by 728
Metadata
- Authors
- Dopheide, J. A., & Pliszka, S. R.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2009-06
- Volume
- 29
- Issue
- 6
- Pages
- 656-679
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W1977761077
- Cited by
- 645
- References
- 134
- FWCI
- 55.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Attention‐Deficit‐Hyperactivity Disorder: An Update. https://app.cochat.ai/papers/10.1592/phco.29.6.656
- The paper
- Dopheide, J. A., & Pliszka, S. R. (2009). Attention‐Deficit‐Hyperactivity Disorder: An Update. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1592/phco.29.6.656
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.